Key result
Crossover trial evaluates ivabradine and propranolol against placebo for POTS.
Why the study?
Postural orthostatic tachycardia syndrome lacks approved pharmacologic therapies and requires comparison of hemodynamic effects of ivabradine and propranolol.
Does ivabradine or propranolol improve hemodynamic effects and patient preference compared to placebo in patients with Postural orthostatic tachycardia syndrome?
RCT (n=22)
Crossover
Does ivabradine or propranolol improve hemodynamic effects and patient preference compared to placebo in patients with Postural orthostatic tachycardia syndrome?
Both ivabradine and propranolol effectively reduce orthostatic tachycardia in POTS compared to placebo, with patient preferences split between the two active treatments.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Symptom and quality-of-life improvements were selective rather than uniform, and patient preferences were divided between active medications, highlighting interindividual variability in tolerability and perceived benefit. Treatment selection should be individualized based on clinical phenotype an...”
Supports individualized ivabradine or propranolol use in POTS due to variable tolerability; hypothesis-generating for symptom-focused trials.
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is characterized by an excessive orthostatic heart rate increase and lacks approved pharmacologic therapies. OBJECTIVES: The objective of the study was to compare hemodynamic effects of ivabradine and propranolol and assess medication preferences in patients with POTS. METHODS: ) in the last 5 to 10 minutes. Prespecified within-participant comparisons were performed between treatments. Treatment preference was recorded at each phase end. RESULTS: between them. Among 22 preferences, all participants preferred ivabradine (P < 0.001) or propranolol (P < 0.001) over placebo, without differences between active treatments (59% vs 41%; P = 0.52). CONCLUSIONS: Ivabradine and propranolol reduce orthostatic tachycardia vs placebo, lowering heart rate below POTS diagnostic criteria. Ivabradine elevates systolic blood pressuremore than propranolol, supporting personalized drug selection. Importantly, heart rate lowering was consistent whereas symptom and quality-of-life effects were more selective, supporting individualized treatment.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Uppal et al. (2026) conducted an RCT in Postural Orthostatic Tachycardia Syndrome (n=22). Ivabradine and propranolol vs. Placebo was evaluated on Treatment preference (p=<0.001). Ivabradine and propranolol were both preferred over placebo by patients with POTS, with no significant difference in preference between the two active treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: